On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...

FDA seeks restrict compounding of GLP-1 drugs by excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list to limit unauthorized use.

May 29—(StatePoint) Most consumers know how a traditional pharmacy works. Far fewer are aware of an alternative option: a compounding pharmacy. Here's everything you need to know about these ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding ...

The proposal could affect telehealth services that rely on outside facilities to produce the knockoff drugs in bulk.

Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...

It is easy to differentiate between your local community pharmacy and a large pharmaceutical manufacturer. The pharmacy is viewed as dispensing medications to particular patients with prescriptions ...

For compounding pharmacies, sourcing active pharmaceutical ingredients (APIs) is about far more than finding the lowest price. Quality, compliance, and supplier reliability directly impact patient ...

Add Yahoo as a preferred source to see more of our stories on Google. Compound drugs are copies of U.S. Food and Drug Administration-approved medications. They are made by licensed pharmacies, but not ...